Sarepta Therapeutics Inc ELEVIDYS FDA Accelerated Approval Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Colin Nigel Bristow - UBS Investment Bank, Research Division - Analyst : And a big congratulations on such a landmark approval. So first question is, what is your expectation for the average time it's going to take for a patient to receive 9001 it's prescribed. I saw the patient journey, I'm not sure if I heard that specific time line. And then also, as we think about sort of exon skippers, what's your expectation around their use and reimbursement in patients who received 9001?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Congratulations to the entire Sarepta team. Can you remind us what other additional endpoints and color you might share with the agency after you have the data later this year? And then would you also plan to continue sharing some of the longer-term data you've been from the earlier conducted trials?

Question: Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division - Analyst : You got some of the approval. So for your approved PMO products, these have broad labels whereas many of the large payer policies today, they have restrictions based on age and ambulation in the clinical trials. So I was just hoping you could describe your historical ability to secure access to these products outside of the published prior authorization criteria.